KALA BIO, Inc.
KALA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479419
No open-market purchases or sales by KALA BIO, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.21M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding KALA BIO, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 56 | 30 | −26 |
| SharesConverted for a 1-for-50 split | 123.3K | 336.2K | +212.9K (+172.6%) |
| Value | $1.36M | $12.8M | +$11.5M (+843.2%) |
New holders (6)
Institutions that held KALA BIO, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Baker Bros. Advisors LP | 76,813 | $2.93M | 0.02% |
| Clear Street LLC | 49,390 | $1.88M | 0.07% |
| Jane Street Group, LLC | 25,953 | $990.1K | 0.00% |
| Two Sigma Securities, LLC | 6,517 | $248.6K | 0.04% |
| Knights of Columbus Asset Advisors LLC | 2,417 | $92.2K | 0.01% |
| MCF Advisors LLC | 230 | $8.77K | 0.00% |
Sold out (32)
Institutions that held KALA BIO, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.